Table 7.
GMTs for neutralizing antibody to each DENV type in primed subjects (ATP cohort for immunogenicity)
| ATP cohort, primed subjects: N = 286 | ||||
|---|---|---|---|---|
| Antibody | Group | Timing | N | GMT (95% CIs) |
| DENV-1 | F17 | PRE | 91 | 564.3 (409.4, 777.8) |
| PI(M3) | 88 | 1161.6 (896.4, 1505.1) | ||
| PII(M7) | 87 | 1412.8 (1191.5, 1675.3) | ||
| F19 | PRE | 94 | 448.5 (311.7, 645.4) | |
| PI(M3) | 93 | 1283.2 (1023.6, 1608.5) | ||
| PII(M7) | 90 | 1324.1 (1104.1, 1587.9) | ||
| DENV-2 | F17 | PRE | 91 | 529.1 (374.2, 748.2) |
| PI(M3) | 88 | 1290.3 (991.5, 1679.2) | ||
| PII(M7) | 87 | 1514.4 (1322.2, 1734.6) | ||
| F19 | PRE | 94 | 448.2 (320.1, 627.4) | |
| PI(M3) | 93 | 1590.1 (1327.8, 1904.2) | ||
| PII(M7) | 90 | 1338.5 (1105.6, 1620.6) | ||
| DENV-3 | F17 | PRE | 91 | 499.1 (351.3, 709.0) |
| PI(M3) | 88 | 1080.7 (802.2, 1456.1) | ||
| PII(M7) | 87 | 1130.0 (920.0, 1388.0) | ||
| F19 | PRE | 94 | 323.5 (217.3, 481.6) | |
| PI(M3) | 93 | 1167.7 (921.7, 1479.4) | ||
| PII(M7) | 90 | 901.4 (707.6, 1148.3) | ||
| DENV-4 | F17 | PRE | 91 | 452.2 (320.7, 637.7) |
| PI(M3) | 88 | 1041.7 (800.5, 1355.7) | ||
| PII(M7) | 87 | 1228.4 (1014.1, 1488.0) | ||
| F19 | PRE | 94 | 349.2 (245.1, 497.5) | |
| PI(M3) | 93 | 1147.5 (908.5, 1449.3) | ||
| PII(M7) | 90 | 1020.8 (809.5, 1287.4) | ||
ATP = according to protocol; 95% CI = 95% confidence intervals; DENV = dengue virus; GMT = geometric mean antibody titer calculated on all subjects; N = number of subjects with available results; PI(M3) = post-dose 1 Month 3 time point; PII(M7) = post-dose 2 Month 7 time point; PRE = pre-vaccination.